FDA approval of a novel non-opioid analgesic will hopefully address the needs of many patients with acute pain and improve ...

According to a Vertex spokesperson, the drug is seeing strong initial market adoption, with growing payer coverage and ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

The Supreme Court last year blocked a previous settlement proposal from Purdue, arguing that the plan would afford the Sackler family too much protection.

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...

After its January FDA approval for moderate to severe acute pain in adults, the company priced Journavx at $15.50 per 50mg tablet.

The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here to read why PCRX stock is a Buy.

Vertex Pharmaceuticals (NasdaqGS:VRTX) saw a notable 20.53% share price increase over the last quarter, which coincided with several key developments in its Type 1 Diabetes (T1D) initiatives. The ...